Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers? - Wikidata - wikimedia - TriplyDB

Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?

Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?

http://www.wikidata.org/entity/Q33416959

about

Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate.Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.A fracture prevention service reduces further fractures two years after incident minimal trauma fracture.

P2860

Q36620541-1EA987F1-D54E-47E6-B227-9CBF570A1900 Q37780535-3606D5A1-10CC-4FF4-9601-E88185680680 Q54295617-21033ECF-06FA-4DE3-BE99-0307EDB9A7CA

P2860

Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?

http://www.wikidata.org/entity/Q33416959

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Treating osteoporosis in Canad ...... red by policy decision makers?

@ast

Treating osteoporosis in Canad ...... red by policy decision makers?

@en

type

label

Treating osteoporosis in Canad ...... red by policy decision makers?

@ast

Treating osteoporosis in Canad ...... red by policy decision makers?

@en

prefLabel

Treating osteoporosis in Canad ...... red by policy decision makers?

@ast

Treating osteoporosis in Canad ...... red by policy decision makers?

@en

P1433

Q33416959-EDD4D23F-8689-44DC-82C5-6357ABAFAD2B

P1476

Q33416959-4BBE6153-C4BD-40FE-A901-1AD439C01930

P2093

Q33416959-6550D233-EF29-4DAD-8083-0449E375421A

Q33416959-7942A2BA-D9A3-4D17-AD10-11CBD318D354

Q33416959-E7BA8C7D-B096-4471-9918-64F9939598E6

Q33416959-E98C323F-62BA-4FF7-9BEF-B7A8E6685F59

Q33416959-FABDCF93-7E97-4900-96C8-C8FE71BFF7EA

P2860

Q33416959-046B667C-6DC5-4D58-A2C5-D338BC368182

Q33416959-048C4090-AB19-43B2-8FBD-89BB3F5285C5

Q33416959-09BE14DD-7FD2-41D6-A08E-1ADBC8C899E2

Q33416959-132D41A7-5961-4E94-8B25-16C7AB611F43

Q33416959-159F70AA-8FEA-4712-A418-C4AFAE402A98

Q33416959-1A5415B0-D9D8-49CF-AE3E-5DDA2754B4ED

Q33416959-1EFAD042-5C78-493B-97FF-5EBD011A6260

Q33416959-2496E049-008A-4F63-B1BE-0F3A2BF826BD

Q33416959-33441F51-BB4D-4D97-A542-6B824D9669C7

Q33416959-446A7C06-394F-4555-B72F-09AAC3F141C6

P2888

Q33416959-871D0354-D2A2-4524-AA3B-4833CC4954A7

P304

Q33416959-12D8FE7D-86C6-4EB2-A9BF-D5062347C1D0

P31

Q33416959-0930B651-E88D-4A25-B250-7ECC9DE658EF

P356

Q33416959-B3930B63-A59E-43D5-9476-B2304C82E0FC

P407

Q33416959-A40CE478-A4BA-4456-8458-D9380A7D16E0

P433

Q33416959-BD169F21-69ED-4FC8-AC73-B203AF67C3BB

P478

Q33416959-9A1883E2-9C6E-4313-8CCE-B84E534728F7

P50

Q33416959-3E8C79AC-8F40-4910-89D4-774832B7438E

P577

Q33416959-F6886967-5E70-429C-B166-CFC5A09FCA86

P6179

Q33416959-9DE3FC06-7545-485A-A580-F7D7D08AC869

P698

Q33416959-37737758-5307-45F8-98DE-9CD911E88A6B

P921

Q33416959-60CD0854-333E-4CAC-B000-6A2F08D87A7E

P932

Q33416959-D07D3149-EB73-44AD-9152-B2D3A67ED103

P356

S00198-009-0870-9

P1433

Osteoporosis International

P1476

Treating osteoporosis in Canad ...... red by policy decision makers?

@en

P2093

A Papaioannou

http://www.w3.org/2001/XMLSchema#string

C C Kennedy

http://www.w3.org/2001/XMLSchema#string

G Ioannidis

http://www.w3.org/2001/XMLSchema#string

J D Adachi

http://www.w3.org/2001/XMLSchema#string

V Walker

http://www.w3.org/2001/XMLSchema#string

P2860

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

Problems in dealing with missing data and informative censoring in clinical trials.

Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials.

A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis.

To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data.

Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.

An overview of methods and empirical comparison of aggregate data and individual patient data results for investigating heterogeneity in meta-analysis of time-to-event outcomes.

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Time to event (survival) data.

Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology.

P2888

s00198-009-0870-9

P304

1785-1793

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00198-009-0870-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

William D. Leslie

P577

2009-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1016650895

http://www.w3.org/2001/XMLSchema#string

P698

19277810

http://www.w3.org/2001/XMLSchema#string

P921

P932

5101050

http://www.w3.org/2001/XMLSchema#string